IL17A and colorectal carcinoma: In this study, we utilized a combination of network pharmacology, molecular docking techniques, and in vivo experiments to demonstrate that SYD effectively improved the intestinal inflammatory environment, inhibited CRC cell proliferation, and promoted its apoptosis by suppressing the phosphorylation of the IL‐17/TNF/NF‐κB signaling pathway.